Payer Moratoriums Block Alma Credentialing
Alma
This reveals the main bottleneck in Alma’s growth is no longer finding therapists, it is getting payer permission to turn those therapists into billable capacity. Alma can recruit clinicians and handle their paperwork in about 45 days, but if a payer slows or freezes new panels, those clinicians sit on a waitlist instead of seeing insured patients. That weakens the core promise of fast network expansion and makes payer relationships as important as therapist acquisition.
-
Alma’s model depends on group credentialing. Therapists join Alma, upload licenses, CAQH data, and malpractice coverage, then get paneled under Alma’s group tax ID with carriers like Optum. If Optum restricts new additions, Alma cannot fully activate the providers it signs up, even if demand from patients is there.
-
This is a market level issue, not just an Alma issue. Headway also depends on payer credentialing, and large incumbents like Optum and Carelon increasingly own both the insurance relationship and parts of the care network. That gives payers a simple lever, they can keep third party platforms in the network, but slow their growth by limiting new slots.
-
The restriction matters more in mental health because these platforms compete on supply density. Headway has over 48,000 therapists, Alma has 20,000 plus providers, and Rula has 15,000 plus therapists. When panel openings are scarce, scale shifts from a recruiting advantage to a queue management problem, and smaller differences in payer access can decide who grows fastest in a state.
The next phase of competition will center on deeper payer integration, not just better therapist software. Platforms that win preferred status, expand plan count, or move into Medicare Advantage and Medicaid will keep compounding. Platforms that rely on broad commercial panel expansion without locked in payer access will face slower network growth and more pressure on retention and economics.